Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by rhdmdon Jan 07, 2013 10:23pm
222 Views
Post# 20808272

My attempt to plain English

My attempt to plain English

 

TLR stands for toll-like receptor. The toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition system, which underpins pathogen recognition by and activation of the immune system. In other words, through evolution, we have these protein structures that has a key way that would recognize pathogens by fitting into/with a certain part of the “non-self” elements which could be bacteria, virus, fungus or cancer cells. Once these receptors bind up with the “foreign or non-self” elements, it will activate the immune system and generate a cascade of cell-killing chemicals, and foreigner-killer cells. Its action is very much like the antibodies. The difference is the antibodies need the B-lymphocytes to be exposed to the foreigners and then it is “custom-made” to recognize and bind with that foreigner. Whereas, the TLR is pre-existing and always there. It develops through evolution and might have parts of it able to recognize and bind with multitude of different foreigners.

The TLR- Agonists essentially act like the foreigners. It binds with the TLR and start the activation process.

Specifically, the TLF-7 receptors reside in the cell compartments of  B-lymphocytes that specialize in making Antibodies, the Macrophage / Monocytes that “eat” the foreigners and the Plasmacytoid dendritetic cells that make the interferon critical for anti-viral immune activities.

 

In this case, Telormedix proprietary TMX-101 is the synthetic molecular keys that can penetrate the cell wall of those cells and fit into and bind with the TLR-7 in them, activating the cancer cell killing process with different agents generated by the immune reaction.

 

One notable point is that they are targeting the CIS tumors. The response rate of Urocidin in this CIS population is 21%. Let’s see what they get.

 

Also the Urocidin is also effective against the non-CIS tumors. We don’t know whether this TMX-101 is effective to that population also. Remains to be seen.

 

Finally, I think the TLR activation is partially the mechanism Urocidin uses.

 

SWNE, I hope this is comprehensible for you!

Bullboard Posts